期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DDP-4抑制剂在2型糖尿病中临床应用进展 被引量：14

Progress in clinical application of DDP-4 inhibitors for type 2 diabetes
原文传递
导出
摘要 目的:二肽基肽酶-4(Dipeptidyl Peptidase-4,DPP-4)可以裂解包括胰高血糖素样肽-1(glucagonlike peptide 1,GLP-1)和抑胃肽(glucose-dependent insulinotropic polypeptide,GIP)在内的多种肽类激素,而前两者与2型糖尿病有着密切联系,是近年来2型糖尿病治疗领域研究的热点。本文就DDP-4抑制剂的作用特点、临床应用以及安全性和耐受性做一综述。方法:通过对国内外近期文献进行分析。结果与结论:DDP-4抑制剂不仅具有良好的降糖效果及保护β细胞功能,并且在糖尿病并发症进展中也起着一定的保护作用。 Objective： Dipeptidyl peptidase-4 （DDP-4） degrades several peptide hormones including glu- cagon-like peptide 1 （GLP-1） and glucose-dependent insulinotropic polypeptide （GIP）. GLP-1 and GIP are closely related to type 2 diabetes. It is the hot area of the treatment of type 2 diabetes in recent years. In this article, we summarized the characteristics, clinical application, safety and tolerability of DDP-4 inhibitors. Methods： The medical literature in recent years at home and abroad was collected and analyzed. Results and Conclusion： DDP- 4 inhibitors have satisfactory hypoglycemic effects and protect β cells, and are beneficial for preventing diabetic complications as well.
作者 杨莉 岳仁宋
机构地区 成都中医药大学附属医院内分泌科
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第23期2753-2757,共5页 Chinese Journal of New Drugs
关键词 DDP4抑制剂 2型糖尿病 临床应用 DPP-4 inhibitors type 2 diabetes clinical application
分类号 R977.1 [医药卫生—药品]
  • 相关文献

参考文献33

  • 1IDF Diabetes Atlas- The Global Burden[EB/OLJ. [2014 -05- 01]. http://www. idf. orgldiabetes atlas/global-burden 2013.
  • 2XU Y, WANG L, HE J, et at. Prevalence and control of diabetes in Chinese adults[J]. lAMA, 2013, 310(9): 948 -959.
  • 3PRATLEY RE, KIPNES MS, FLECK PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy[J]. Diabetes Obes Metab, 2009, 11 (2): 167 -176.
  • 4FREDERICH R, MCNEILL R, BERGLIND N, et at. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial[J] . Diabetol Metab Syndr, 2012,4 ( 1 ) :36.
  • 5MONAMI M, IACOMELLI I, MARCHIONNI N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials [J]. Nutr Metab Cardiovasc Dis, 2010, 20 (4) : 224 - 235.
  • 6ROSENSTOCK J, GROSS JL, SALINAS CA. Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes [J]. Diabetes, 2011,60 (Suppl 1): A289 - A298.
  • 7SUAREZ-PINZON WL, CEMBROWSKI GS, RABINOVITCH A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice[Jl.Diabetologia, 2009,52(8) :1680 -1682.
  • 8MONAMI M, AHREN B, DICEMBRINI I, et at. Dipeptidyl peptidase - 4 inhibitors and cardiovascular risk: a meta - analysis of randomized clinical trials [J]. Diabetes Obes Metab , 2013,15(2): 112 -120.
  • 9BOSCHMANN M, ENGELI S, DOBBERSTEIN K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients [J]. I Clin Endocrinol Metab, 2009,94(3) :846 -852.
  • 10FERREIRA L, TEIXEIRA-DE-LEMOS E, PINTO F, et al. Effects of sitagliptin treatment on dysmetabolism , inflammation, and oxidative stress in an animal model of type 2 diabetes (ZD F rat) [J]. Mediators Inflamm, 2010, 2010 (2010): 1155 - 1165.

二级参考文献57

  • 1黄建权,傅得兴,胡欣,张君仁.抗糖尿病药物维达列汀[J].中国新药杂志,2007,16(6):486-488. 被引量：11
  • 2KODA-KIMBLE MA著,王秀兰,张淑文译.临床药物治疗学[M].第8版.北京:人民卫生出版社,2007:50:3-4.
  • 3THORNBERRY NA, WEBER AE. Discovery of JANUVIA (Sitagliptin) , a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [ J ]. Curr Top Med Chem, 2007, 7 (6) : 557 -568.
  • 4HAVALE SH, PAL M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes [ J ]. Bioorg Med Chem, 2009, 17 ( 5 ) : 1783 - 1802.
  • 5EDMONDSON SD, MASTRACCHIO A, DUFFY JL, et al. Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors [ J ].Bioorg Med Chem Lett, 2005, 15(12) : 3048 -3052.
  • 6DEACON CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes [ J ]. Curr Opin lnvestig Drugs, 2008, 9(4) : 402 -413.
  • 7AUGERI DJ, ROBL JA, BETEBENNER DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118) : a highly potent, long-acting, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes[ J]. J Med Chem, 2005, 48(15) : 5025 -5037.
  • 8BRAZG R, THOMAS K, ZHAO P, et al. Effect of adding MK- 0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin [ J]. Diabetes, 2005, 54(Suppl 1):A3.
  • 9CHARBONNEL B, KARASIK A. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 dabetes inadequately controlled with metformin alone [ J ]. Diabetes Care, 2006, 29 (12) : 2638 - 2643.
  • 10NAUCK M, MEINININGER G, SHENG D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulphonylurea glipizidein patients with type 2 diabetes inadequately controlled on mefformin alone: a randomized, double-blind, non-inferiority trial [ J ]. Diabetes Obes Metab, 2007, 9(2) :194 -205.

共引文献25

同被引文献135

  • 1郑静,王刚.胃肠道微生态与中医基础理论[J].陕西中医学院学报,2007,30(1):10-12. 被引量：29
  • 2KAHN SE, COOPER ME, DEL PS. Pathophysiology and treat- ment of type 2 diabetes: perspectives on the past, present, and future [ J ]. Lancet, 2014, 383 (9922) : 1068 - 1083.
  • 3CAMPBELL RK, COBBLE ME, REID TS, et al. Pathophysiolo- gy of type 2 diabetes mellitus: Potential role of incretin-based therapies [ J ]. J Faro Pract, 2010, 59 ( Suppl 1 ) : $5 - $9.
  • 4NATHAN DM, BUSE JB, DAVIDSON MB, et al. Medical man- agement of hyperglycaemia in type 2 diabetes mellitus: a consen- sus algorithm for the initiation and adjustment of therapy: a con- sensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [ J~. Diabetolo- gia, 2009, 52(1): 17-30.
  • 5INZUCCHI SE. Oral antihyperglycemic therapy for type 2 diabe- tes : scientific review [ J ]. JAMA, 2002, 287 (3) : 360 - 372.
  • 6TZOULAKI I, MOLOKHIA M, CURCIN V, et al. Risk of cardi- ovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database [ J~. BMJ, 2009, 339: b4731.
  • 7CDR Clinical Review Report for Onglyza[ R]. Canadian Agency for Drugs and Technologies in Health, 2013. AWMSG Secretariat Assessment Report-Advice No. 2011.
  • 8Saxaglip- tin (Onglyza~ ) November 2011 [ R]. All Wales Therapeutics and Toxicology Centre, 2011.
  • 9AWMSG Secretariat Assessment Report-Advice No. 2012 Saxa- gliptin ( Onglyza~ ) June 2012 ~ R 1. All Wales Therapeutics and Toxicology Centre, 2012.
  • 10AWMSG Secretariat Assessment Report. Saxagliptin ( Onglyza~ ) 2.5 mg and 5 mg film-coated tablets. Reference number: 1975. October 2013 [ R ]. All Wales Therapeutics and Toxicology Cen- tre, 2013.

引证文献14

二级引证文献44

中国新药杂志
2014年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部